Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 363.56
NAS:NLNK's Cash-to-Debt is ranked higher than
54% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:NLNK: 363.56 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:NLNK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.79  Med: 49.17 Max: 363.56
Current: 363.56
0.79
363.56
Equity-to-Asset 0.76
NAS:NLNK's Equity-to-Asset is ranked higher than
59% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:NLNK: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:NLNK' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.11  Med: 0.76 Max: 0.93
Current: 0.76
-5.11
0.93
Debt-to-EBITDA -0.01
NAS:NLNK's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:NLNK: -0.01 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:NLNK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.66  Med: -0.06 Max: 0.01
Current: -0.01
-0.66
0.01
Piotroski F-Score: 5
Altman Z-Score: 3.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -232.47
NAS:NLNK's Operating Margin % is ranked lower than
55% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:NLNK: -232.47 )
Ranked among companies with meaningful Operating Margin % only.
NAS:NLNK' s Operating Margin % Range Over the Past 10 Years
Min: -2849.13  Med: -964.85 Max: 68.12
Current: -232.47
-2849.13
68.12
Net Margin % -229.18
NAS:NLNK's Net Margin % is ranked lower than
55% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:NLNK: -229.18 )
Ranked among companies with meaningful Net Margin % only.
NAS:NLNK' s Net Margin % Range Over the Past 10 Years
Min: -2852.7  Med: -966.19 Max: 55.63
Current: -229.18
-2852.7
55.63
ROE % -60.70
NAS:NLNK's ROE % is ranked lower than
58% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:NLNK: -60.70 )
Ranked among companies with meaningful ROE % only.
NAS:NLNK' s ROE % Range Over the Past 10 Years
Min: -85.27  Med: -52.36 Max: 75.23
Current: -60.7
-85.27
75.23
ROA % -45.62
NAS:NLNK's ROA % is ranked lower than
56% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:NLNK: -45.62 )
Ranked among companies with meaningful ROA % only.
NAS:NLNK' s ROA % Range Over the Past 10 Years
Min: -86.63  Med: -59.94 Max: 63.63
Current: -45.62
-86.63
63.63
ROC (Joel Greenblatt) % -1134.96
NAS:NLNK's ROC (Joel Greenblatt) % is ranked lower than
61% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:NLNK: -1134.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:NLNK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1134.96  Med: -386.28 Max: 1042.38
Current: -1134.96
-1134.96
1042.38
3-Year Revenue Growth Rate 206.20
NAS:NLNK's 3-Year Revenue Growth Rate is ranked higher than
98% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:NLNK: 206.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:NLNK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 64.15 Max: 209.3
Current: 206.2
0
209.3
3-Year EBITDA Growth Rate 34.70
NAS:NLNK's 3-Year EBITDA Growth Rate is ranked higher than
82% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:NLNK: 34.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:NLNK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.1 Max: 34.7
Current: 34.7
0
34.7
3-Year EPS without NRI Growth Rate 33.70
NAS:NLNK's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:NLNK: 33.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:NLNK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.3 Max: 33.7
Current: 33.7
0
33.7
GuruFocus has detected 3 Warning Signs with NewLink Genetics Corp NAS:NLNK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:NLNK's 30-Y Financials

Financials (Next Earnings Date: 2018-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

NLNK Guru Trades in Q4 2016

First Eagle Investment 5,713 sh (unchged)
First Eagle Investment 2,129,200 sh (-2.63%)
Jim Simons 145,800 sh (-57.96%)
» More
Q1 2017

NLNK Guru Trades in Q1 2017

Joel Greenblatt 12,976 sh (New)
Steven Cohen 40,000 sh (New)
Charles Brandes 9,173 sh (New)
First Eagle Investment 2,299,200 sh (+7.98%)
First Eagle Investment 3,690 sh (unchged)
Jim Simons 47,900 sh (-67.15%)
» More
Q2 2017

NLNK Guru Trades in Q2 2017

Paul Tudor Jones 38,916 sh (New)
Jim Simons 214,904 sh (+348.65%)
First Eagle Investment 2,444,200 sh (+6.31%)
First Eagle Investment 3,190 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Charles Brandes Sold Out
» More
Q3 2017

NLNK Guru Trades in Q3 2017

Steven Cohen 178,680 sh (New)
Louis Moore Bacon 50,000 sh (New)
Paul Tudor Jones 40,714 sh (+4.62%)
First Eagle Investment 2,494,200 sh (+2.05%)
First Eagle Investment 2,278 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:NLNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2017-09-30 Add 2.05%$6.35 - $17.67 $ 9.188%2,494,200
First Eagle Investment 2017-06-30 Add 6.31%$6.07 - $24.1 $ 9.18-35%2,444,200
Charles Brandes 2017-06-30 Sold Out $6.07 - $24.1 $ 9.18-35%0
Joel Greenblatt 2017-06-30 Sold Out $6.07 - $24.1 $ 9.18-35%0
First Eagle Investment 2017-03-31 Add 7.98%0.01%$10.55 - $24.1 $ 9.18-42%2,299,200
Joel Greenblatt 2017-03-31 New Buy$10.55 - $24.1 $ 9.18-42%12,976
Charles Brandes 2017-03-31 New Buy$10.55 - $24.1 $ 9.18-42%9,173
First Eagle Investment 2016-12-31 Reduce -2.63%$10.01 - $16.42 $ 9.18-27%2,129,200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:ROCO:4128, NAS:KURA, NAS:RARX, XPAR:COX, LSE:OBD, AMEX:BTX, XBRU:TIG, XKRX:087010, NAS:CRVS, TSX:HSM, NAS:VCYT, ASX:MVF, LSE:MPH, SZSE:000004, NAS:NVAX, OSTO:ONCO, NAS:CLDX, XKRX:001630, NAS:MRUS, AMEX:XXII » details
Traded in other countries:4NX.Germany,
Headquarter Location:USA
NewLink Genetics Corp is a clinical stage immuno-oncology company based in US. It focuses on developing novel immunotherapeutic products for the treatment of cancer. Its portfolio contains biologic and small-molecule immuno-oncology product candidates.

NewLink Genetics is an American biotechnology company targeting immunotherapeutic products to improve treatment options for patients with cancer. The company's portfolio contains biologic and small-molecule immuno-oncology product candidates intended to treat a wide variety of oncology indications. Its products are based on the proprietary HyperAcute Cellular Immunotherapy technology, which is expected to stimulate the human immune system.

Ratios

vs
industry
vs
history
PB Ratio 2.70
NLNK's PB Ratio is ranked higher than
65% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NLNK: 2.70 )
Ranked among companies with meaningful PB Ratio only.
NLNK' s PB Ratio Range Over the Past 10 Years
Min: 1.63  Med: 5.84 Max: 21.18
Current: 2.7
1.63
21.18
PS Ratio 8.60
NLNK's PS Ratio is ranked higher than
62% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. NLNK: 8.60 )
Ranked among companies with meaningful PS Ratio only.
NLNK' s PS Ratio Range Over the Past 10 Years
Min: 4.33  Med: 55.21 Max: 1081.4
Current: 8.6
4.33
1081.4
EV-to-EBIT -3.02
NLNK's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. NLNK: -3.02 )
Ranked among companies with meaningful EV-to-EBIT only.
NLNK' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.9  Med: -8.05 Max: 13.5
Current: -3.02
-36.9
13.5
EV-to-EBITDA -3.09
NLNK's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. NLNK: -3.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
NLNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38  Med: -8.3 Max: 13.4
Current: -3.09
-38
13.4
EV-to-Revenue 7.02
NLNK's EV-to-Revenue is ranked higher than
72% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. NLNK: 7.02 )
Ranked among companies with meaningful EV-to-Revenue only.
NLNK' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.7  Med: 53.8 Max: 1046.8
Current: 7.02
1.7
1046.8
Current Ratio 5.14
NLNK's Current Ratio is ranked higher than
57% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. NLNK: 5.14 )
Ranked among companies with meaningful Current Ratio only.
NLNK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 9.06 Max: 25.95
Current: 5.14
0.97
25.95
Quick Ratio 5.14
NLNK's Quick Ratio is ranked higher than
58% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. NLNK: 5.14 )
Ranked among companies with meaningful Quick Ratio only.
NLNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 9.06 Max: 25.95
Current: 5.14
0.97
25.95
Days Sales Outstanding 125.69
NLNK's Days Sales Outstanding is ranked lower than
86% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. NLNK: 125.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
NLNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.42  Med: 159.67 Max: 617.06
Current: 125.69
26.42
617.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.10
NLNK's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. NLNK: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NLNK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.6  Med: -6.95 Max: 0
Current: -3.1
-23.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.29
NLNK's Price-to-Net-Cash is ranked higher than
73% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. NLNK: 3.29 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NLNK' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.5  Med: 7.76 Max: 29.76
Current: 3.29
2.5
29.76
Price-to-Net-Current-Asset-Value 2.85
NLNK's Price-to-Net-Current-Asset-Value is ranked higher than
81% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. NLNK: 2.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NLNK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.23  Med: 6.2 Max: 21.93
Current: 2.85
2.23
21.93
Price-to-Tangible-Book 2.70
NLNK's Price-to-Tangible-Book is ranked higher than
73% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. NLNK: 2.70 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NLNK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.1  Med: 5.71 Max: 14.64
Current: 2.7
2.1
14.64
Price-to-Median-PS-Value 0.16
NLNK's Price-to-Median-PS-Value is ranked higher than
96% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. NLNK: 0.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NLNK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 0.74 Max: 12.24
Current: 0.16
0.09
12.24
Earnings Yield (Greenblatt) % -32.90
NLNK's Earnings Yield (Greenblatt) % is ranked lower than
80% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. NLNK: -32.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NLNK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.9  Med: -8.15 Max: 16.7
Current: -32.9
-95.9
16.7

More Statistics

Revenue (TTM) (Mil) $31.32
EPS (TTM) $ -2.44
Beta1.56
Short Percentage of Float34.74%
52-Week Range $5.90 - 25.17
Shares Outstanding (Mil)37.08

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -2.55 -1.62
EPS without NRI ($) -2.55 -1.62
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}